Oral Anti-Diabetic Drugs Market to Reach US$ 80.8 Billion by 2031, Growing at 8.0% CAGR, Driven by Rising Diabetes Prevalence and Biosimilar Expansion | DataM Intelligence

According to DataM Intelligence, the global Oral Anti-Diabetic Drugs market reached US$ 44.3 billion in 2022 and is projected to reach US$ 80.8 billion by 2031, growing at a CAGR of 8.0% during the forecast period 2024-2031. This growth is propelled by the escalating global diabetes epidemic, increasing adoption of biguanides (metformin) and DPP-4 inhibitors, rapid biosimilar penetration improving affordability, strong demand for combination therapies, expanding access through online and retail pharmacies, and ongoing innovation in oral formulations for better patient compliance.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/oral-anti-diabetes-drugs-market?jd

United States Key Industry Developments
☑️ January 2026: Novo Nordisk continued strong performance of oral semaglutide (Rybelsus), with expanded insurance coverage and real-world evidence supporting its use in type 2 diabetes management.
☑️ January 2026: Merck reported increased adoption of Januvia (sitagliptin) and Janumet combinations, bolstered by new generic competition and patient assistance programs.
☑️ December 2025: Sanofi expanded its Amaryl (glimepiride) and other sulfonylurea offerings through retail pharmacy partnerships, targeting cost-conscious patients.
☑️ December 2025: Glenmark Pharma launched new fixed-dose combinations of metformin and DPP-4 inhibitors, gaining traction in the U.S. generic market.

Japan Key Industry Developments
☑️ January 2026: Japanese authorities approved additional generic versions of key DPP-4 inhibitors and biguanides, accelerating reimbursement and adoption in outpatient diabetes care.
☑️ January 2026: Local and global players, including Takeda (partnered with others), showcased advanced oral anti-diabetic portfolios at major endocrinology conferences in Tokyo.
☑️ December 2025: Growing use of SGLT2 inhibitors (oral class expansions) and metformin combinations in urban clinics, driven by rising type 2 diabetes prevalence and government metabolic health initiatives.

Key Mergers and Acquisitions
✦ Eli Lilly and Company progressed integration of recent acquisitions in metabolic health, including assets with potential crossover benefits for oral anti-diabetic pipelines (ongoing January 2026 updates).
✦ Novo Nordisk continued strategic bolt-on deals and collaborations to enhance its oral GLP-1 and combination therapy offerings for type 2 diabetes.
✦ Sun Pharma secured licensing agreements with innovators for next-generation oral anti-diabetic molecules, positioning for biosimilar and novel drug launches in 2026.

Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=oral-anti-diabetes-drugs-market

Market Segmentation Analysis
By Drug Class: Biguanides (metformin) dominate; followed by DPP-4 Inhibitors, Sulfonylureas, Alpha-glucosidase Inhibitors, Meglitinides, Dopamine-D2 Receptor Agonists, and Others.
By Dosage Type: Tablets lead; followed by Capsules and Liquid formulations.
By Distribution Channel: Retail Pharmacies and Hospital Pharmacies hold the largest shares; Online Pharmacies grow rapidly.

Regional Insights
North America commands the largest market share in the global Oral Anti-Diabetic Drugs market, supported by high diabetes prevalence, advanced healthcare infrastructure, widespread adoption of branded and generic orals, favorable reimbursement for diabetes management, and strong presence of leading pharmaceutical companies driving innovation and access.
Asia-Pacific remains the fastest-growing region, fueled by rapidly rising diabetes burden in populous countries, increasing healthcare expenditure, rapid biosimilar adoption, expanding online and retail pharmacy networks, government initiatives for chronic disease control, and aggressive market entry by global and local manufacturers.

Growth Drivers
✦ Escalating global type 2 diabetes incidence and prediabetes awareness
✦ Strong preference for oral therapies due to convenience and compliance
✦ Rapid biosimilar entry reducing costs for DPP-4 inhibitors and biguanides
✦ Advancements in fixed-dose combinations and next-generation oral agents
✦ Expanding distribution through e-commerce and retail channels

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/oral-anti-diabetes-drugs-market?jd

Key Players
The market includes leading companies such as Glenmark Pharma, Abbott, Biocon, Sanofi S.A., Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, Bristol-Myers Squibb, and others.

Key Highlights (Top 5 Key Players)
✦ Novo Nordisk - Leading with oral semaglutide (Rybelsus) and strong GLP-1 class expansion.
✦ Merck - Dominating through Januvia (sitagliptin) and combination therapies.
✦ Sanofi - Strong in sulfonylureas and broad diabetes portfolio.
✦ Novartis - Advancing DPP-4 inhibitors and fixed-dose combinations.
✦ Biocon - Growing rapidly with affordable biosimilars in emerging markets.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.